Home 5 Articles 5 CMS Restores Medicare Coverage of Certain Genetic Thyroid Cancer Tests

CMS Restores Medicare Coverage of Certain Genetic Thyroid Cancer Tests

by | Mar 10, 2022

The first two months of 2022 have been quite eventful for Interpace Biosciences. On Jan. 13, the personalized medicine firm announced it had initiated a $30 million subscription rights offering. But on Jan. 28, Interpace said it was pulling out of the deal in response to a new Centers for Medicare & Medicaid Services’ (CMS) […]

The first two months of 2022 have been quite eventful for Interpace Biosciences. On Jan. 13, the personalized medicine firm announced it had initiated a $30 million subscription rights offering. But on Jan. 28, Interpace said it was pulling out of the deal in response to a new Centers for Medicare & Medicaid Services’ (CMS) […]

This content is Exclusive to Lab Industry Report Subscribers

Subscribe or Log in for Exclusive Access.